SPOT ON
Post-marketing trials without tangible benefit
NEW ON THE MARKET
Anti-interleukin-5 antibody reslizumab (CINQAERO) for severe eosinophilic asthma
THERAPY FROM A CRITICAL VIEWPOINT
Delirium in palliative care: neuroleptics worse than placebo
Tapentadol (PALEXIA, YANTIL): What
IN BRIEF
Migraine prevention in children: is placebo the best medicine?
Death following overdose of colchicine - the package size of the drop formulation is to be limited
France: zolpidem (STILNOX, generics) -narcotic prescription required
Glucosamine and chondroitin in osteoarthritis without benefit in yet another study
CURRENT ADR NETWORK REPORT
Urticaria with apixaban (ELIQUIS)
SIDE EFFECTS
Malformations with hydroxyethylrutoside (e.g. VENORUTON)?
Fatalities with selexipag (UPTRAVI) in pulmonary hypertension
Rivaroxaban (XARELTO): agranulocytosis and STEVENS-JOHNSON syndrome free article
e a-t ON THE INTERNET
Elbasvir plus Grazoprevir (ZEPATIER) for hepatitis C
Amputations with SGLT2 inhibitors
Once more: anaphylactic reactions with chlorhexidine